Sign in
LLY-ELI LILLY & CO

Eli Lilly Reports Impressive Q4 Earnings with 45% Revenue Growth, Outperforming Analysts' Expectations and Strengthening Optimistic 2025 Projections

Tuesday

18 February, 2025

Eli Lilly's remarkable Q4 earnings reveal a 45% revenue growth, driven by the success of its weight loss drug, Zepbound, which generated $1.9 billion in sales. With analysts projecting a strong 32% growth rate for 2025, can Eli Lilly maintain its momentum in the competitive biopharma landscape?

article image for LLY

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
71
Key Takeaways
  • Eli Lilly boasts a substantial market value of $799.5 billion and a notable stock rise of 24.6% in the last year.
  • The company achieved remarkable fourth-quarter results, with adjusted earnings per share reaching $5.32 and a 45% revenue surge.
  • Analysts project a "Strong Buy" rating, anticipating sales between $58-$61 billion by 2025, indicating a 32% growth.
  • Expansion in production for Zepbound and Mounjaro strengthens its position in the anti-obesity market.
  • A significant 103% dividend increase over five years makes Eli Lilly appealing for long-term investors.
More on ELI LILLY & CO
Read more insights on ELI LILLY & CO

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.